Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.
OBJECTIVE
To study the effects of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori (H pylori).


METHODS
Forty-eight patients with hyperplastic gastric polyps (3-10 mm in diameter) infected with H pylori were randomly assigned to a treatment group (n = 24) which received proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole, and a control group (n = 24) which received protective agent of gastric mucosa (tepretone). Patients underwent endoscopy and H pylori examination regularly before enrollment and 1-12 mo after treatment.


RESULTS
Twenty-two patients in the treatment group and 21 in the control group completed the entire test protocol. In the treatment group, polyps disappeared 1-12 mo (average, 6.5+/-1.1 mo) after the treatment in 15 of 22 patients (68.2%) and H pylori infection was eradicated in 19 of the 22 patients (86.4%). However, 12 months after the study, no change in polyps or H pylori status was seen in any controls ((b)P<0.01).


CONCLUSIONS
Most hyperplastic gastric polyps disappear after eradication of H pylori.
Ji
Feng
F
First Affiliated Hospital, Medicine School of Zhejiang University, Hangzhou 310003, Zhejiang Provice, China. jifeng1126@sina.com
Wang
Zi-Wei
ZW
Ning
Jian-Wen
JW
Wang
Qun-Yan
QY
Chen
Jian-Yong
JY
Li
You-Ming
YM
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000517:prevention & control; D016480:Helicobacter pylori; D006801:Humans; D015994:Incidence; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D011127:Polyps / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology* / Q000473:pathology; D054328:Proton Pump Inhibitors; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology* / Q000473:pathology; D014011:Tinidazole / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D014011:Tinidazole; D064747:Lansoprazole; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole